natgillin/translations-raw huggingface dataset:
Data from pooled clinical studies in patients with systemic iron overload show that 63% of the episodes of agranulocytosis occurred within the first six months of treatment, 74% within the first year and 26% after one year of therapy. 
Združeni podatki iz kliničnih študij, pridobljeni pri bolnikih s sistemsko preobremenitvijo z železom kažejo, da se je 63 % primerov agranulocitoze pojavilo v prvih šestih mesecih zdravljenja, 74 % v prvem letu in 26 % po enem letu zdravljenja.
Adverse reaction frequencies: Very common (≥1/10), Common (≥1/100 to <1/10), not known (cannot be estimated from the available data). 
Tabelarični pregled neželenih učinkov Pogostost neželenih učinkov: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The response to therapy should be assessed periodically, and the occurrence of adverse events closely monitored. 
Odziv bolnika na zdravljenje je treba periodično ocenjevati in pozorno spremljati pojav neželenih učinkov.
Sucralose (E955) 
sukraloza (E955)
Use the measuring cup to measure the volume prescribed by your doctor. 
Z merilno posodico izmerite količino, ki vam jo je predpisal zdravnik.
Even though agranulocytosis only affects 1 to 2 out of 100 users, it is important to monitor your blood on a regular basis. 
Čeprav se agranulocitoza pojavi le pri 1 do 2 od 100 bolnikov, je zelo pomembno, da redno opravljate krvne teste.
− if you are pregnant or breast-feeding. 
− če ste noseči ali dojite.
The median time to onset of the first episode of agranulocytosis was 190 days (ranged 22 days- 17.6 years) and median duration was 10 days in clinical trials. 
Mediana časa do pojava prve epizode agranulocitoze je bila 190 dni (v razponu od 22 dni do 17,6 let), mediana trajanja v kliničnih preskušanjih pa je bila 10 dni.
There was an improvement in cardiac T2* of more than 3 ms in patients treated with Ferriprox compared with a change of about 1 ms in patients treated with deferoxamine. 
Prišlo je do izboljšanja v srčnem T2* za več kot 3 ms pri pacientih, ki so jih zdravili z zdravilom Ferriprox v primerjavi s spremembo približno 1 ms pri pacientih, ki so jih zdravili z deferoksaminom.
It is not known whether deferiprone is excreted in human milk. 
Ni znano, ali se deferipron izloča v materino mleko.
Dose adjustments should be tailored to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). 
Odmerek naj se prilagodi odzivu posameznika in terapevtskim ciljem (vzdrževanje ali zmanjševanje prekomerne količine železa v telesu).
In most cases, the pain disappeared while patients continued taking Ferriprox. 
V večini primerov so bolečine izginile, medtem ko so bolniki nadaljevali z jemanjem zdravila Ferriprox.
((Inside 1)) 
((1. notranja stran))
FOR WOMEN OF CHILD BEARING AGE 
((zadnja stran)) ZA ŽENSKE V RODNI DOBI
In the event of agranulocytosis, rechallenge is contraindicated. 
V primeru agranulocitoze je ponovna uporaba kontraindicirana.
Increased levels of serum liver enzymes have been reported in some patients taking deferiprone. 
Povečana količina serumskih encimov v jetrih je bila opažena pri nekaterih pacientih, ki jemljejo deferipron.
Some patients experienced progression of fibrosis associated with an increase in iron overload or hepatitis C. 
Pri nekaterih bolnikih je prišlo do napredovanja fibroze, povezane s povečanjem obremenitve z železom ali s hepatitisom C.
The use of combination therapy should be considered on a case-by-case basis. 
Za sočasno zdravljenje se je treba odločati na podlagi vsakega posameznega primera.
Cardiac endpoints were assessed by echocardiogram, electrocardiogram, the New York Heart Association classification and death due to cardiac disease. 
Srčne mejne vrednosti so določili z ehokardiogramom, elektrokardiogramom in po klasifikaciji organizacije New York Heart Association ter smrti zaradi srčne bolezni.
This metabolite lacks iron-binding capability due to inactivation of the 3-hydroxy group of deferiprone. 
Ta presnovek nima sposobnosti vezave železa zaradi inaktivacije 3-hidroksilne skupine deferiprona.
Gastrointestinal effects are more frequent at the beginning of therapy and resolve in most patients within a few weeks without the discontinuation of treatment. 
Učinki na prebavila so pogostejši na začetku zdravljenja z deferipronom in v večini primerov izzvenijo v nekaj tednih, ne da bi prekinili zdravljenje.
A total daily dose above 100 mg/kg body weight is not recommended because of the potentially increased risk of adverse reactions (see sections 4.4, 4.8, and 4.9). 
Skupni dnevni odmerek nad 100 mg/kg telesne mase ni priporočen zaradi možnega zvečanega tveganja za neželene učinke (glejte poglavja 4.4, 4.8 in 4.9).
Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia. 
Zdravljenje z deferipronom naj uvede in nadzira zdravnik, ki ima izkušnje z zdravljenjem bolnikov s talasemijo.
Ferriprox will be most effective if you do not miss any doses. 
Zdravilo Ferriprox bo najbolj učinkovito, če ne boste pozabili vzeti niti enega odmerka.
Important Safety Reminders for Patients taking Ferriprox (deferiprone) Prescribing doctor: _________________ Phone No: ________________________ 
Pomembna opozorila glede varnosti bolnikov, ki jemljejo zdravilo Ferriprox (deferipron) Zdravnik, ki je predpisal zdravilo:________________________
Neurological disorders have been observed in children treated with more than 2.5 times the maximum recommended dose for several years but have also been observed with standard doses of deferiprone. 
Nevrološke motnje so opazili pri otrocih, ki so jih nekaj let zdravili z več kot 2,5-kratnim najvišjim priporočenim odmerkom, opazili pa so jih tudi pri standardnih odmerkih deferiprona.
In clinical trials, weekly monitoring of the neutrophil count has been effective in identifying cases of neutropenia and agranulocytosis. 
V kliničnih preskušanjih se je tedensko spremljanje števila nevtrofilcev izkazalo za učinkovito pri odkrivanju primerov nevtropenije in agranulocitoze.
The amount of Ferriprox that you take will depend on your weight. 
Količina zdravila Ferriprox, ki ga boste jemali, je odvisna od vaše telesne mase.
Number of tablets (three times/day) 
Število tablet (trikrat/dan)
The safety of concurrent use of deferiprone and vitamin C has not been formally studied. 
Varnost sočasne uporabe deferiprona in vitamina C ni preučena.
Evening 
Zvečer
Evaluation of rate of reactions per 100 patient-years of exposure showed that only the rate of diarrhoea was significantly higher in children (11.1) than in adults (2.0, p=0.01). 
Ocena stopnje reakcij na 100 bolnikov-let izpostavljenosti je pokazala, da je le stopnja driske bistveno višja pri otrocih (11,1) kot pri odraslih (2,0, p = 0,01).
If treatment is unavoidable, breast-feeding must be stopped (see section 4.3). 
Če je zdravljenje neizogibno, je treba prenehati z dojenjem (glejte poglavje 4.3).
At the same time point, LVEF had increased from baseline by 3.07 ± 3.58 absolute units (%) in the Ferriprox group and by 0.32 ± 3.38 absolute units (%) in the deferoxamine group (difference between groups; p=0.003). 
Hkrati se je LVEF povečal z osnovnega nivoja za 3,07 ± 3,58 absolutnih enot (%) v skupini, ki je jemala Ferriprox, in za 0,32 ± 3,38 absolutnih enot (%) v skupini, ki je jemala deferoksamin (razlika med skupinama; p = 0,003).
This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken Ferriprox in clinical studies. 
Takšno stanje, znano kot tudi huda nevtropenija ali agranulocitoza, se je pojavilo pri 1 do 2 od 100 ljudi, ki so jemali zdravilo Ferriprox v kliničnih študijah.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
- Preobčutljivost za učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1
Regardless of the degree of renal impairment, the majority of the dose of Ferriprox was excreted in the urine over the first 24 hours as deferiprone 3-O-glucuronide. 
Ne glede na stopnjo ledvične okvare je bil odmerek zdravila Ferriprox v večini izločen z urinom v prvih 24 urah v obliki deferipron-3-O-glukuronida.
If you do miss one dose take it as soon as you remember and take your next dose at its regularly scheduled time. 
Če pozabite na odmerek, ga vzemite takrat, ko se na to spomnite, naslednji odmerek pa po običajnem razporedu.
The genotoxic potential of deferiprone was evaluated in a set of in vitro and in vivo tests. 
Genotoksični potencial deferiprona je bil ocenjen v nizu preskusov in vitro ter in vivo.
5 years. 
5 dni/teden).
An increase in MRI T2* on treatment indicates that iron is being removed from the heart. 
Povečanje MRI T2* med zdravljenjem nakazuje, da se železo odstranjuje iz srca.
Women of childbearing potential must be advised to avoid pregnancy due to the clastogenic and teratogenic properties of the medicinal product. 
Ženskam v rodni dobi je treba svetovati, naj ne zanosijo zaradi klastogenih in teratogenih lastnosti zdravila.
Deferiprone did not show direct mutagenic properties; however, it did display clastogenic characteristics in in vitro assays and in animals. 
Pri deferipronu se niso pokazale neposredne mutagene lastnosti; pokazale pa so se klastogene lastnosti pri in vitro testih in pri živalih.
The active substance is deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a bidentate ligand which binds iron in a 3:1 molar ratio. 
Učinkovina je deferipron (3-hidroksi-1,2-dimetilpiridin-4-on), bidentatni ligand, ki železo veže v molarnem razmerju 3:1.
In addition he or she might ask you to undergo liver biopsies. 
Poleg tega vas bo morda napotil na biopsijo jeter.
If you have accidentally taken more than the prescribed dose, you should contact your doctor. 
Če ste po nesreči vzeli večji odmerek od predpisanega, obvestite svojega zdravnika.
The change from weekly ANC monitoring to at the time of transfusion visits after 12 months of Ferriprox therapy, should be considered on an individual patient basis, according to the physician's assessment of the patient's understanding of the risk minimization measures required during therapy (see section 4.4 below). 
Prehod s tedenskega spremljanja ANC na interval za transfuzijo po 12 mesecih zdravljenja z zdravilom Ferriprox je treba pretehtati za vsakega posameznega bolnika glede na zdravnikovo oceno bolnikovega razumevanja ukrepov za zmanjšanje tveganj, ki so potrebni med zdravljenjem (glejte poglavje 4.4 spodaj).
Doses of Ferriprox in those studies ranged from 50 to 100 mg/kg/day and doses of deferoxamine from 40 to 60 mg/kg/day. 
Odmerki zdravila Ferriprox v teh študijah so se gibali v razponu od 50 do 100 mg/kg/dan in odmerki deferoksamina od 40 do 60 mg/kg/dan.
Prescribers are reminded that the use of doses above 100 mg/kg/day are not recommended. 
Predpisovalci zdravila se morajo zavedati, da uporaba odmerkov, večjih od 100 mg/kg/dan, ni priporočljiva.
This may be extended to 2 hours in fed patients. 
Ta čas se pri bolnikih, ki so že jedli, lahko podaljša na 2 uri.
These women should be advised to take contraceptive measures and must be advised to immediately stop taking deferiprone if they become pregnant or plan to become pregnant (see section 4.3). 
Svetovati jim je treba uporabo ustrezne kontracepcije in takojšnje prenehanje uporabe deferiprona, če zanosijo ali načrtujejo zanositev (glejte poglavje 4.3).
• To increase patient awareness of the importance of regular monitoring of the neutrophil count during treatment with deferiprone 
• za informiranje bolnikov o pomembnosti rednega spremljanja števila nevtrofilcev med zdravljenjem z deferipronom;
Ferriprox is an iron chelator, a type of medicine that removes excess iron from the body. 
Zdravilo Ferriprox je kelator železa - vrsta zdravila, ki iz telesa odstrani odvečno železo.
In these patients careful monitoring of liver histology is recommended. 
Pri teh bolnikih je priporočljivo pazljivo histološko nadzorovanje jeter.
Peak serum concentration occurs 45 to 60 minutes following a single dose in fasted patients. 
Najvišjo koncentracijo v serumu doseže 45 do 60 minut po enkratnem odmerku pri bolnikih, ki zdravilo vzamejo na tešče.
The risk of agranulocytosis and neutropenia is higher if the baseline ANC is less than 1.5x109/l. 
Nevarnost agranulocitoze in nevtropenije je višja, če je osnovno ANC manjše od 1,5 x 109/l.
Ferriprox was concluded to produce no significant prolongation of the QT interval. 
Ugotovljeno je bilo, da zdravilo Ferriprox ne podaljšuje bistveno intervala QT.
It is recommended that such a management protocol be in place prior to initiating any patient on deferiprone treatment. 
Priporočamo, da se ta postopek izpelje, preden se pri katerem koli bolniku uvede zdravljenje z deferipronom.
For patients whose Ferriprox has not been interrupted during the first year of therapy due to any decrease in the neutrophil count, the frequency of ANC monitoring may be extended to the patient's blood transfusion interval (every 2-4 weeks) after one year of deferiprone therapy. 
Pri bolnikih, pri katerih je bilo zdravljenje z zdravilom Ferriprox v prvem letu prekinjeno zaradi zmanjšanja števila nevtrofilcev, je dovoljeno pogostnost spremljanja ANC po enem letu zdravljenja z deferipronom podaljšati na bolnikov interval za transfuzijo krvi (vsake 2-4 tedne).
Since deferiprone binds to metallic cations, the potential exists for interactions between deferiprone and trivalent cation-dependent medicinal products such as aluminium-based antacids. 
Ker pa se deferipron veže na kovinske katione, obstaja možnost interakcij med deferipronom in zdravili s trivalentnimi kationi, kot so antacidi, ki vsebujejo aluminijeve spojine.
A fatal outcome was observed in 8.3% of the reported episodes of agranulocytosis from clinical trials and post-marketing experience. 
Smrtni izid so opazili pri 8,3 % epizod agranulocitoze iz kliničnih preskušanj in izkušenj v obdobju trženja, o katerih so poročali.
Ferriprox in combination with another chelator (see section 4.4) is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction (see section 4.2). 
Zdravilo Ferriprox je v kombinaciji z drugim kelatorjem (glejte poglavje 4.4) indicirano pri bolnikih s talasemijo major, če je monoterapija s katerim koli kelatorjem železa neučinkovita, ali kadar preprečevanje ali zdravljenje življenjsko nevarnih posledic preobremenitve z železom (predvsem srčne preobremenitve) opravičuje hiter ali intenziven popravek (glejte poglavje 4.2).
In thalassaemia patients there is an association between liver fibrosis and iron overload and/or hepatitis C. Special care must be taken to ensure that iron chelation in patients with hepatitis C is optimal. 
Pri bolnikih s talasemijo je dokazana povezava med fibrozo jeter in prekomerno količino železa v telesu in/ali hepatitisom C. Posebno pozorno je potrebno preveriti, da je keliranje železa pri bolnikih s hepatitisom C optimalno.
Ferriprox and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p >0.05). 
Ferriprox in deferoksamin sta si bila enakovredna pri stabilizaciji ali zmanjševanju količine železa v telesu navkljub neprekinjeni transfuzijski aplikaciji železa pri teh pacientih (brez razlike v deležu pacientov z negativno tendenco pri serumskem feritinu med dvema obravnavanima skupinama pri analizi regresije; p > 0,05).
Study LA37-1111 was conducted to evaluate the effect of single therapeutic (33 mg/kg) and supratherapeutic (50 mg/kg) oral doses of deferiprone on the cardiac QT interval duration in healthy subjects. 
V študiji LA37-1111 je bil ocenjevan učinek enkratnega terapevtskega (33 mg/kg) in supraterapevtskega (50 mg/kg) peroralnega odmerka deferiprona na trajanje intervala QT pri zdravih preiskovancih.
What Ferriprox is and what it is used for What you need to know before you take Ferriprox How to take Ferriprox 
Kaj je zdravilo Ferriprox in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Ferriprox Kako jemati zdravilo Ferriprox
• To increase patient awareness of the significance of any symptoms of infection while taking deferiprone 
• za informiranje bolnikov o pomembnosti vsakršnih simptomov okužbe med jemanjem deferiprona;
The levels normalised with oral zinc supplementation. 
Vrednosti so se normalizirale s peroralnim dopolnjevanjem cinka.
Dose adjustments when used with other iron chelators In patients for whom monotherapy is inadequate, Ferriprox may be used with deferoxamine at the standard dose (75 mg/kg/day) but should not exceed 100 mg/kg/day. 
Prilagoditve odmerka pri uporabi z drugimi kelatorji železa Pri bolnikih, pri katerih je monoterapija neprimerna, se zdravilo Ferriprox lahko uporablja z deferoksaminom v standardnem odmerku (75 mg/kg/dan), vendar ne sme preseči 100 mg/kg/dan.
Systemic exposure to deferiprone and to its metabolite deferiprone 3-O-glucuronide was assessed by the PK parameters Cmax and AUC. 
Sistemska izpostavljenost deferipronu in njegovemu presnovku deferipron 3-O-glukuronidu je bila ocenjena s farmakokinetičnima parametroma Cmax in AUC.
No carcinogenicity studies in animals have been conducted with deferiprone. 
Študije o karcinogenem delovanju deferiprona pri živalih niso bile izvedene.
− if you have a history of repeated episodes of neutropenia (low white blood cell (neutrophil) 
− če ste kdaj imeli ponavljajoče se epizode nevtropenije (znižana koncentracija belih krvničk
Dose per kilogram body weight should be calculated to the nearest half tablet. 
Odmerek na kilogram telesne mase naj se izračuna do najbližje polovice tablete natančno.
A variable amount of elimination via the faeces has been reported. 
Poročali so tudi o spremenljivi količini izločanja v blatu.
The higher rate of “Cardiac disorders" reported during combination therapy than monotherapy was possibly due to the higher incidence of pre-existing cardiac disorders in patients who received combination therapy. 
Višja stopnja »srčnih bolezni«, o katerih so poročali med kombinirano terapijo, v primerjavi z monoterapijo, je verjetno posledica večje pojavnosti obstoječih srčnih bolezni pri bolnikih, ki so prejemali kombinirano terapijo.
The influence of severe hepatic impairment on the pharmacokinetics of deferiprone and deferiprone 3-O-glucuronide has not been evaluated. 
Vpliva hude jetrne okvare na farmakokinetiko deferiprona in deferiprona 3-O-glukuronida niso ovrednotili.
PATIENT/CARER REMINDER CARD ((Front Cover)) 
OPOZORILNA KARTICA ZA BOLNIKA/SKRBNIKA ((naslovna stran))
The safety profile of combination therapy (deferiprone and deferoxamine) observed in clinical trials, post-marketing experience or published literature was consistent with that characterized for monotherapy. 
Varnostni profil sočasnega zdravljenja (deferiprona in deferoksamina), ki so ga opazili v kliničnih preskušanjih, pri izkušnjah v času trženja zdravila ali v objavljeni literaturi, se je skladal s tistim, ki je značilen za monoterapijo.
Discoloration of urine 
Sprememba barve urina
Study LA12-9907 compared survival, incidence of cardiac disease, and progression of cardiac disease in 129 patients with thalassaemia major treated for at least 4 years with Ferriprox (N=54) or deferoxamine (N=75). 
Študija LA12-9907 je primerjala obstoj, pojav in napredovanje srčne bolezni pri 129 pacientih z veliko talasemijo, ki so jih vsaj 4 leta zdravili z zdravilom Ferriprox (N = 54) ali deferoksaminom (N = 75).
The incidences of adverse reactions experienced by 18 children and 97 adults treated with combination therapy were not significantly different between the two age groups except in the incidence of arthropathy (11.1% in children vs. none in adults, p=0.02). 
Pojavnost neželenih učinkov pri 18 otrocih in 97 odraslih, zdravljenih s kombinirano terapijo, se med starostnima skupinama ni bistveno razlikovala, razen v pojavnosti artropatije (11,1 % pri otrocih v primerjavi z 0 % pri odraslih, p = 0,02).
Studies LA16-0102, LA-01 and LA08-9701 compared the efficacy of Ferriprox with that of deferoxamine in controlling serum ferritin in transfusion-dependent thalassaemia patients. 
V študijah LA16-0102, LA-01 in LA08-9701 so primerjali učinkovitost zdravila Ferriprox in deferoksamina pri nadziranju serumskega feritina pri pacientih s talasemijo, ki so odvisni od transfuzije.
Should any evidence of infection develop concurrently with the neutropenia, the appropriate cultures and diagnostic procedures should be performed and an appropriate therapeutic regimen instituted. 
Če se hkrati z nevtropenijo pojavijo kakršnikoli znaki okužbe, je treba odvzeti kužnine za kulturo, opraviti primerne diagnostične postopke ter vpeljati primerno zdravljenje.
The neurological disorders progressively regressed after deferiprone discontinuation. 
Nevrološke funkcije so se progresivno izboljšale po prekinitvi jemanja deferiprona.
Data from the published literature are consistent with the results from the Apotex studies, demonstrating less heart disease and/or increased survival in Ferriprox-treated patients than in those treated with deferoxamine. 
Podatki iz objavljene literature se ujemajo z rezultati študij Apotexa, kjer so ugotovili manj srčnih bolezni in/ali povečano stopnjo preživetja pri pacientih, ki so jemali Ferriprox namesto deferoksamina.
If the patient develops an infection while on deferiprone, therapy should be immediately interrupted, and an ANC obtained without delay. 
Če se pri bolniku, ki jemlje deferipron, razvije okužba, je treba zdravljenje prekiniti in takoj preveriti ANC.
Deferiprone must not be used by breast-feeding mothers. 
Deferiprona ne smejo jemati doječe matere.
Clinical studies have demonstrated that Ferriprox is effective in promoting iron excretion and that a dose of 25 mg/kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia. 
Klinične študije so pokazale, da je Ferriprox učinkovit pri spodbujanju izločanja železa in da lahko odmerek 25 mg/kg trikrat na dan prepreči naraščanje akumulacije železa (ocenjeno z merjenjem serumskega feritina) pri bolnikih s talasemijo, ki so odvisni od transfuzije.
Therefore, it is not recommended to concomitantly ingest aluminium-based antacids and deferiprone. 
Zato ni priporočljivo sočasno jemanje antacidov, ki vsebujejo aluminijeve spojine, in deferiprona.
Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but fatal cases of agranulocytosis have been reported. 
Agranulocitoza in nevtropenija navadno izzvenita po prekinitvi zdravljenja z zdravilom Ferriprox, so pa poročali o smrtnih primerih agranulocitoze.
Your white blood cell count must be checked within 24 hours in order to detect potential agranulocytosis. 
V 24 urah je treba preveriti število belih krvnih celic, da bi prepoznali morebitno agranulocitozo.
It is packaged in bottles of 250 ml or 500 ml. 
Pakirana je v plastenkah po 250 ml ali 500 ml.
Patients should be informed that their urine may show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. 
Bolnike je potrebno poučiti o možnosti, da lahko njihov urin postane rdečkastorjavo obarvan zaradi izločanja kompleksa železo-deferipron.
Deferiprone is metabolised predominantly to a glucuronide conjugate. 
Deferipron se v glavnem presnavlja v konjugiran glukuronid.
Keep the bottle tightly closed in order to protect from moisture. 
Steklenička naj bo trdno zaprta, da je vsebina zaščitena pred vlago.
Do not take this medicine if you are pregnant or if you are trying to become pregnant. 
Zdravila ne jemljite, če ste noseči ali poskušate zanositi.